Clinical Trial Detail

NCT ID NCT03083808
Title Phase II Trial of Continuation Therapy in Advanced NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Greg Durm
Indications

lung non-small cell carcinoma

Therapies

Gemcitabine + Pembrolizumab

Docetaxel + Pembrolizumab

Pembrolizumab + Pemetrexed Disodium

Pemetrexed Disodium

Age Groups: senior adult

No variant requirements are available.